Divisions of Infectious Diseases, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
Department of Pathology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Viral Immunol. 2021 Oct;34(8):504-509. doi: 10.1089/vim.2021.0054. Epub 2021 Jul 5.
Early results suggest that SARS-CoV-2 vaccines are highly effective for the prevention of COVID-19. Unfortunately, until we can safely, rapidly, and affordably vaccinate enough people to achieve collective immunity, we cannot afford to disregard the benefits of naturally acquired immunity in those, whose prior documented infections have already run their course. As long as the vaccine manufacturing, supply, or administration are limited in capacity, vaccination of individuals with naturally acquired immunity at the expense of others without any immune protection is inherently inequitable, and violates the principle of justice in biomedical ethics. Any preventable disease acquired during the period of such unnecessary delay in vaccination should not be overlooked, as it may and will result in some additional morbidity, mortality, related hospitalizations, and expense. Low vaccine production capacity complicated by inefficiencies in vaccine administration suggests, that vaccinating preferentially those without any prior protection will result in fewer natural infections more rapidly.
早期结果表明，SARS-CoV-2 疫苗在预防 COVID-19 方面非常有效。不幸的是，在我们能够安全、快速和负担得起地为足够多的人接种疫苗以实现群体免疫之前，我们不能忽视那些先前有记录的感染已经过去的人的自然获得性免疫的益处。只要疫苗的制造、供应或管理能力有限，以牺牲没有任何免疫保护的人为代价为那些自然获得免疫的人接种疫苗，从本质上讲是不公平的，违反了生物医学伦理中的正义原则。在这种不必要的疫苗接种延迟期间获得的任何可预防疾病都不应被忽视，因为它可能而且确实会导致一些额外的发病率、死亡率、相关住院治疗和费用。疫苗接种管理效率低下导致疫苗生产能力低下，这表明优先为那些没有任何先前保护的人接种疫苗将更快地导致更少的自然感染。
